Ironwood Pharmaceuticals Inc. (IRWD) Trading 5.3% Higher
Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) traded up 5.3% during trading on Tuesday . The stock traded as high as $13.97 and last traded at $13.96, with a volume of 415,254 shares trading hands. The stock had previously closed at $13.26.
Several equities research analysts recently issued reports on IRWD shares. Zacks Investment Research raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a report on Monday, July 25th. Barclays PLC increased their target price on shares of Ironwood Pharmaceuticals from $11.00 to $12.00 and gave the stock an “equal weight” rating in a report on Friday, August 5th. Wedbush reissued a “neutral” rating and issued a $10.00 target price on shares of Ironwood Pharmaceuticals in a report on Thursday, August 4th. JPMorgan Chase & Co. increased their target price on shares of Ironwood Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Friday, August 5th. Finally, Leerink Swann reissued a “market perform” rating and issued a $14.00 target price (up from $10.00) on shares of Ironwood Pharmaceuticals in a report on Monday, August 8th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Ironwood Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $15.20.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/06/ironwood-pharmaceuticals-inc-irwd-trading-5-3-higher/
The firm has a 50-day moving average of $13.68 and a 200-day moving average of $11.91. The firm’s market capitalization is $2.03 billion.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Thursday, August 4th. The company reported ($0.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.15) by $0.01. The company earned $54.40 million during the quarter, compared to analysts’ expectations of $54.49 million. During the same quarter in the prior year, the firm earned ($0.34) EPS. The company’s revenue was up 96.4% compared to the same quarter last year. Analysts anticipate that Ironwood Pharmaceuticals Inc. will post ($0.76) earnings per share for the current fiscal year.
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders.
Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.